BD is investing approximately $1.2 billion to expand manufacturing capacity for pre-fillable syringes (PFS) and advanced drug delivery systems (ADDS) across its six global manufacturing locations, including adding a new facility in Europe
The new manufacturing facility in Europe is expected to be operational by the end of 2023. The investment will also fund capacity expansion, new product innovations, manufacturing technology enhancements and business continuity improvements across its existing network, all designed to maximise supply and reduce risks for pharmaceutical companies that rely on ready-to-fill syringes for their injectable drugs — including complex biologics, vaccines and small molecules.
This investment positions BD to have the needed surge capacity for increased pre-fillable syringe demand during times of pandemic response or periods of significant growth of new injectable drugs and vaccines.
